[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532574":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":46,"centralContacts":51,"locations":62,"responsibleParty":79,"collaborators":28,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":28,"enrollmentInfo":91,"targetDuration":28,"studyType":94,"phases":95,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Tata Memorial Centre","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Systemic therapy","ACTIVE_COMPARATOR","Participants will receive one of the following Gemcitabine-based systemic therapy alone:\n\n1. Gemcitabine plus cisplatin:\n\n   Gemcitabine 1000mg\u002Fm2 and Cisplatin 25 mg\u002Fm2, each administered on Days 1 and 8 every 3 weeks (q3w)\n2. Gemcitabine plus oxaliplatin:\n\n   Gemcitabine 1000 mg\u002Fm2 and oxaliplatin 100 mg\u002Fm2 IV infusion on days 1 and 8 q2w.\n3. Gemcitabine plus cisplatin plus Durvalumab:\n\n   Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg\u002Fm2 and gemcitabine 1000 mg\u002Fm2 each administered on Days 1 and 8, q3w.\n4. Gemcitabine plus cisplatin plus nab-paclitaxel:\n\nGemcitabine 800 mg\u002Fm2, cisplatin, 25 mg\u002Fm2, and nab-paclitaxel 100 mg\u002Fm2, on days 1 and 8, q3w.\n\nduration: 3 months",[13,14,15,16],"Drug: Systemic therapy (Gemcitabine plus Cisplatin)","Drug: Systemic therapy (Gemcitabine plus oxaliplatin)","Drug: Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)","Drug: Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)",{"label":18,"type":10,"description":19,"interventionNames":20},"RT (Radiation therapy)","Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.\n\nThis is followed by systemic therapy as in the Systemic therapy arm",[13,21,14,15,16],"Radiation: RT",[23,29,34,38,42],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Systemic therapy (Gemcitabine plus Cisplatin)","Participants will receive one of the following Gemcitabine-based systemic therapy alone:\n\nGemcitabine 1000mg\u002Fm2 and Cisplatin 25 mg\u002Fm2, each administered on Days 1 and 8 every 3 weeks (q3w)\n\nDuration: 3 months (in addition to 3 months previously received)",[18,9],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"RADIATION","RT","Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.\n\nThis is followed by systemic therapy as in the Systemic therapy alone arm.",[18],{"type":24,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"Systemic therapy (Gemcitabine plus oxaliplatin)","Gemcitabine 1000 mg\u002Fm2 and oxaliplatin 100 mg\u002Fm2 IV infusion on days 1 and 8 q2w.\n\nDuration: 3 months",[18,9],{"type":24,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)","Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg\u002Fm2 and gemcitabine 1000 mg\u002Fm2 each administered on Days 1 and 8, q3w.\n\nDuration 3 months Durvalumab (12 months)",[18,9],{"type":24,"name":43,"description":44,"armGroupLabels":45,"otherNames":28},"Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)","Gemcitabine 800 mg\u002Fm2, cisplatin, 25 mg\u002Fm2, and nab-paclitaxel 100 mg\u002Fm2, on days 1 and 8, q3w Duration: 3 months",[18,9],[47],{"name":48,"affiliation":49,"role":50},"Shivakumar Gudi, MD","Assistant Professor, Radiation Oncology","PRINCIPAL_INVESTIGATOR",[52,57],{"name":48,"role":53,"phone":54,"phoneExt":55,"email":56},"CONTACT","+912224177000","6863","shivakumargudi@gmail.com",{"name":58,"role":53,"phone":59,"phoneExt":60,"email":61},"Reena Engineer, MD","+91222417000","7165","reena.engineer@gmail.com",[63],{"facility":5,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"RECRUITING","Mumbai","Maharashtra","400012","India","IN",{"type":71,"coordinates":72},"Point",[73,74],72.88261,19.07283,{"lat":74,"lon":73},[77,78],{"name":48,"role":53,"phone":54,"phoneExt":55,"email":56},{"name":58,"role":53,"phone":54,"phoneExt":60,"email":61},{"type":50,"investigatorFullName":80,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Shivakumar Gudi","100532574","phase-2-radiation-therapy-in-unresectable-gall-bladder-cancer-100532574",false,"NCT06214572","Radiation Therapy in Unresectable Gall Bladder Cancer","Systemic Therapy With or Without Radiation Therapy in Unresectable Nonmetastatic Gall Bladder Carcinoma: Open Label, Parallel Arm, Phase 2\u002F3 Integrated Randomized Clinical Trial","RUGB","Inclusion Criteria:\n\n* Histologically proven (biopsy\u002Fcytology) adenocarcinoma of gall bladder. Gall bladder neck primaries with hilar block mimicking hilar cholangiocarcinoma will also be included.\n* Non metastatic at presentation as determined using cross sectional imaging and diagnostic laparoscopy if done as a part of standard work up recommended in the joint clinic.\n* Locally advanced disease with one or more of the following\n* Extensive liver infiltration not amenable for surgery but feasible for safe radiation delivery (Liver minus gross tumor volume at least 700cc)\n* Vascular involvement: encasement (\\>180-degree angle) of one of the vessels: Hepatic artery, main portal vein, right or left portal vein\n* Obstructive jaundice with hilar involvement (type 2 non communicating block and higher blocks as per Bismuth-Corlette classification)\n* Stable disease or partial response (RECIST 1.1) after initial 3 months of Gemcitabine based chemotherapy\n* More than 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 fit for chemotherapy\n* Normal hematological and renal and hepatic functions allowing safe delivery of chemotherapy\n* Hematological- Hb\\> 80 g\u002FL, ANC ≥ 1.5 x 109\u002FL, platelets ≥ 100 x 109\u002FL.\n* Liver functions- bilirubin ≤ 2 x upper limit normal (ULN), AST\u002FALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN) S. albumin ≥ 30 g\u002FL\n* Renal function- Creatinine ≤ 1.5 ULN, Creatinine clearance \\>= 50 mL\u002Fmin\n\nExclusion Criteria:\n\n* Patients with distant metastasis (including nonregional lymph nodes metastasis) will be excluded.\n* Prior abdominal therapeutic radiation\n* Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix\n* Pregnancy\u002FLactating women","ALL","18 Years",{"count":92,"type":93},249,"ESTIMATED","INTERVENTIONAL",[96,97],"PHASE2","PHASE3","The goal of this clinical trial is to compare two treatment regimes, namely, systemic therapy (chemotherapy and\u002For immunotherapy) alone vs. systemic therapy and radiation therapy in patients with inoperable but localized gallbladder cancer. The main questions it aims to answer are:\n\n* Whether adding radiation therapy to systemic therapy improves overall survival?\n* What are the effects on other endpoints like cancer-free intervals, side effects, and quality of life? Participants will be randomly assigned to one of the two treatment regimes mentioned earlier by a computer-based program. Researchers will compare survival and quality of life outcomes between the two groups.",[100],"Gall Bladder Cancer",[102,100,103,104],"Biliary tract cancer","Radiation therapy","Unresectable","2025-04-08",{"date":107,"type":108},"2025-04-11","ACTUAL",{"date":110,"type":108},"2024-03-07",{"date":112,"type":93},"2029-07-21",{"name":5,"class":6},1]